EIKN · Eikon Therapeutics, Inc.
AI read · Neutral
The AI's read
Response rates differed by prior treatment: 31% among people who had not previously taken a PARP cancer drug, versus 6% among those who had. Severe side effects affected 43% of the single-drug group and 45% of the abiraterone group. The combination studies showed early signs of activity, but the varied results and side effects leave Eikon’s outlook unchanged for now.